<DOC>
	<DOC>NCT00454402</DOC>
	<brief_summary>The aim of the study is to assess the effect of Alfuzosin compared with placebo, for 7 days, on the outcome of patients with uretheric stones submitted to Extracorporeal Shock Wave Lithotripsy (ESWL), namely in the percentage of patients without imagiologic evidence of any stone after 72h to 96 hours. This study will also specifically focus on the evaluation of time of stone clearance and of pain reduction (Numeric Rating Scale).</brief_summary>
	<brief_title>ALF-STONE: Alfuzosin in Uretheric Stones</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Inclusion criteria: Patients with imagiologic evidence of uretheric stones Exclusion criteria: Women pregnant or breast feeding Patients with renal impairment (creatinine &gt; 2mg/dl) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>